Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 6/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 5/20 | 0.43 |
| ▸ | DRD2 | P14416 | 4/20 | 0.43 |
| ▸ | HTR6 | P50406 | 4/20 | 0.43 |
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7461070 | 0.91 | OPRM1 (0.48) | OPRM1OPRK1OPRL1HTR1ASLC6A4 | |
| Hydrochloric Acid SCHEMBL9031803 | 0.87 | OPRM1 (0.55) | OPRM1OPRK1OPRL1HTR1ASLC6A4 | |
| SCHEMBL7453440 | 0.86 | OPRM1 (0.54) | OPRM1OPRK1OPRL1HTR1ASLC6A4 | |
| Hydrochloric Acid SCHEMBL9044421 | 0.85 | OPRM1 (0.53) | OPRM1OPRK1OPRL1HTR1ASLC6A4 | |
| SCHEMBL9049200 | 0.81 | HTR1A (0.44) | HTR1ASLC6A4HTR7DRD2HTR6 | |
| SCHEMBL5363538 | 0.79 | CYP1A2 (0.60) | OPRM1OPRK1OPRL1HTR1AHTR6 | |
| SCHEMBL9030371 | 0.78 | HRH3 (0.57) | SLC6A4ADRA1DADRA1AADRA1B | |
| SCHEMBL7455861 | 0.78 | SLC6A4 (0.53) | HTR1ASLC6A4HTR7DRD2HTR6 | |
| SCHEMBL7459958 | 0.77 | HTR1A (0.53) | HTR1ASLC6A4HTR7DRD2HTR6 | |
| Hydrochloric Acid SCHEMBL9031667 | 0.76 | SLC6A4 (0.61) | OPRM1OPRK1OPRL1HTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ LP (CA) | 2026-05-07 | — | — | US | disclosed |
| WO-2024073845-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ, LIMITED PARTNERSHIP (CA) | 2024-04-11 | — | — | WO | disclosed |
| EP-0708102-B1 | 5-HT1F agonists for the treatment of migraine | LILLY CO ELI (US) | 2002-12-11 | — | — | EP | disclosed |
| EP-0708102-A1 | 5-HT1F agonists for the treatment of migraine | ELI LILLY AND COMPANY (US) | 1996-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | HTR1F, HTR1A, HTR1D | OPRM1 218/4885OPRK1 266/4885OPRL1 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.